Abstract
ATP citrate lyase (ACLY), an important enzyme involved in lipid biogenesis linked with glucose metabolism, catalyzes the conversion of citrate to oxaloacetic acid (OAA) and acetyl-CoA. The obtained acetyl-CoA is required for lipid synthesis during membrane biogenesis, as well as for histone acetylation reactions to regulate the expression of certain proteins in aberrantly proliferating cancer cells. Studies have shown a role for ACLY in tumorigenesis whereby increased levels of the enzyme leads to increased metabolic activity via activation of Akt signaling. Increasing lines of evidence suggest that enzymes involved in lipid biogenesis play a significant role in cancer cell proliferation and progression. In many cancer types such as glioblastoma, colorectal cancer, breast cancer, non-small cell lung cancer, hepatocellular carcinoma etc., the level of ACLY has been found to be quite high as compared to normal cells. Cancer cell growth related to overexpression of ACLY can be inhibited by using chemical inhibitors or by the knockdown of ACLY gene. Inhibition of ACLY leads to changes in cancer cell metabolism that promotes tumor growth and proliferation. This review summarizes the role of ACLY in cancer development and its inhibitors in cancer treatment.
Keywords: Acetyl-CoA, ATP citrate lyase, cancer, chemoprevention, treatment.
Current Drug Targets
Title:ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and Treatment
Volume: 16 Issue: 2
Author(s): Amrita Devi Khwairakpam, Mayengbam Singh Shyamananda, Bethsebie Lalduhsaki Sailo, Sivakumar Raju Rathnakaram, Ganesan Padmavathi, Jibon Kotoky and Ajaikumar B. Kunnumakkara
Affiliation:
Keywords: Acetyl-CoA, ATP citrate lyase, cancer, chemoprevention, treatment.
Abstract: ATP citrate lyase (ACLY), an important enzyme involved in lipid biogenesis linked with glucose metabolism, catalyzes the conversion of citrate to oxaloacetic acid (OAA) and acetyl-CoA. The obtained acetyl-CoA is required for lipid synthesis during membrane biogenesis, as well as for histone acetylation reactions to regulate the expression of certain proteins in aberrantly proliferating cancer cells. Studies have shown a role for ACLY in tumorigenesis whereby increased levels of the enzyme leads to increased metabolic activity via activation of Akt signaling. Increasing lines of evidence suggest that enzymes involved in lipid biogenesis play a significant role in cancer cell proliferation and progression. In many cancer types such as glioblastoma, colorectal cancer, breast cancer, non-small cell lung cancer, hepatocellular carcinoma etc., the level of ACLY has been found to be quite high as compared to normal cells. Cancer cell growth related to overexpression of ACLY can be inhibited by using chemical inhibitors or by the knockdown of ACLY gene. Inhibition of ACLY leads to changes in cancer cell metabolism that promotes tumor growth and proliferation. This review summarizes the role of ACLY in cancer development and its inhibitors in cancer treatment.
Export Options
About this article
Cite this article as:
Khwairakpam Devi Amrita, Shyamananda Singh Mayengbam, Sailo Lalduhsaki Bethsebie, Rathnakaram Raju Sivakumar, Padmavathi Ganesan, Kotoky Jibon and Kunnumakkara B. Ajaikumar, ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and Treatment, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450115666141224125117
DOI https://dx.doi.org/10.2174/1389450115666141224125117 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Characterization of ROSA Dye - A Rhodamine B-type Fluorophore, Suitable for Bioconjugation and Fluorescence Studies in Live Cells
Protein & Peptide Letters HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Exocrine Pancreas Involvement in Celiac Disease: A Review
Recent Patents on Inflammation & Allergy Drug Discovery S1P Regulation of Macrophage Functions in the Context of Cancer
Anti-Cancer Agents in Medicinal Chemistry Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Folic Acid Conjugated Nanocarriers for Efficient Targetability and Promising Anticancer Efficacy for Treatment of Breast Cancer: A Review of Recent Updates
Current Pharmaceutical Design Synthesis and <i>In silico</i> Studies of Quinazolinone Derivatives as PARP-1 Inhibitors
Letters in Drug Design & Discovery Glycosphingolipid Structure and Function in Membranes
Current Organic Chemistry The Clinical Characteristics and Survival Profiles of Wilms Tumor in the United Arab Emirates: A Single-center Retrospective Analysis
New Emirates Medical Journal Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies
Anti-Cancer Agents in Medicinal Chemistry The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Cutting Edge: Chemoprevention of Colorectal Neoplasia in Inflammatory Bowel Disease
Inflammation & Allergy - Drug Targets (Discontinued) Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Mucoadhesive Formulation Designs for Oral Controlled Drug Release at the Colon
Current Pharmaceutical Design Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets Aryl and Acyclic Unsaturated Derivatives of Thioguanine and 6- Mercaptopurine: Synthesis and Cytotoxic Activity
Letters in Drug Design & Discovery Regulation of MicroRNAs in Inflammation-Associated Colorectal Cancer: A Mechanistic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets